|1.||Yang, Peiying: 2 articles (11/2015 - 09/2008)|
|2.||Pan, Yong: 1 article (11/2015)|
|3.||Kundra, Vikas: 1 article (11/2015)|
|4.||Jiang, Yan: 1 article (11/2015)|
|5.||Fischer, Susan M: 1 article (11/2015)|
|6.||Tan, Lin: 1 article (11/2015)|
|7.||Gagea, Mihai: 1 article (11/2015)|
|8.||Ravoori, Murali K: 1 article (11/2015)|
|9.||Subbaramaiah, Kotha: 1 article (09/2008)|
|10.||Newman, Robert A: 1 article (09/2008)|
04/01/1980 - "In hypercalcemic, tumor-bearing rabbits, the plasma concentrations of 13,14-dihydro-15-keto-PGE2 and 13,14-dihydro-15-keto-PGF2 alpha were markedly elevated (in the range of 0.5 to 16 ng/ml). "
11/17/2015 - "Taken together, these findings suggest that COX-2 deletion contributes to the repression of K-ras-induced lung tumorigenesis by reducing tumor cell proliferation, decreasing the production of PGE2, and increasing the production of 13,14-dihydro-15-keto-PGE2, possibly via the MAPK pathway. "
11/17/2015 - "Compared with lung tumors from K-Ras mice, the levels of prostaglandin E2 (PGE2) were significantly lower, whereas levels of the PGE2 metabolite 13,14-dihydro-15-keto-PGE2 were significantly higher, in lung tumors from K-ras/COX-2-/- mice. "
12/01/1984 - "In all five experiments performed, tumor-bearing mice eating control diets had markedly elevated (average sixfold above control) plasma concentrations of 13,14-dihydro-15-keto-PGE2 (PGE2-M), while in mice bearing HSDM1 tumors and eating the EPA-enriched menhaden oil diet, the elevation was reduced to only twice control values. "
04/01/1978 - "PGE2 secreted by the tumor is rapidly metabolized and can be measured in plasma as the metabolite 13,14-dihydro-15-keto-PGE2 (PGE2-M). "
|2.||Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
09/01/1986 - "Plasma level of 13,14-dihydro-15-keto-PGE2 in patients with diabetic ketoacidosis and in normal fasting subjects."
09/01/1986 - "Plasma levels of 13,14-dihydro-15-keto-PGE2, a stable derivative of PGE2, are elevated in rats with diabetic ketoacidosis (DKA) and decrease in response to insulin therapy. "
|3.||Lung Neoplasms (Lung Cancer)
|5.||Hypotension (Low Blood Pressure)
08/01/1990 - "Arterial levels of 13,14-dihydro-15-keto-PGE2 (PGE2-M), a stable metabolite of prostaglandin E2 (PGE2) were compared between unanesthetized pregnant (n = 12) and nonpregnant (n = 8) rabbits with the aim of elucidating the role PGE2 in the development of physiological hypotension associated with pregnancy. "
|2.||6-Ketoprostaglandin F1 alpha (6 Ketoprostaglandin F1 alpha)
|5.||Prostaglandins F (PGF)